- Home
- SWX vs IDYA Comparison
SWX vs IDYA Comparison
Compare SWX & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWX
- IDYA
- Stock Information
- Founded
- SWX 1931
- IDYA 2015
- Country
- SWX United States
- IDYA United States
- Employees
- SWX N/A
- IDYA N/A
- Industry
- SWX Oil & Gas Production
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- SWX Utilities
- IDYA Health Care
- Exchange
- SWX Nasdaq
- IDYA Nasdaq
- Market Cap
- SWX N/A
- IDYA 2.5B
- IPO Year
- SWX N/A
- IDYA 2019
- Fundamental
- Price
- SWX $74.32
- IDYA $30.90
- Analyst Decision
- SWX Hold
- IDYA Strong Buy
- Analyst Count
- SWX 3
- IDYA 10
- Target Price
- SWX $73.67
- IDYA $56.00
- AVG Volume (30 Days)
- SWX 285.0K
- IDYA 969.0K
- Earning Date
- SWX 11-06-2024
- IDYA 11-05-2024
- Dividend Yield
- SWX 3.34%
- IDYA N/A
- EPS Growth
- SWX N/A
- IDYA N/A
- EPS
- SWX 2.53
- IDYA N/A
- Revenue
- SWX $5,300,147,000.00
- IDYA $11,961,000.00
- Revenue This Year
- SWX N/A
- IDYA N/A
- Revenue Next Year
- SWX $0.27
- IDYA $94.96
- P/E Ratio
- SWX $29.32
- IDYA N/A
- Revenue Growth
- SWX N/A
- IDYA N/A
- 52 Week Low
- SWX $56.17
- IDYA $23.41
- 52 Week High
- SWX $78.47
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- SWX 56.35
- IDYA 42.42
- Support Level
- SWX $72.11
- IDYA $28.69
- Resistance Level
- SWX $74.46
- IDYA $31.54
- Average True Range (ATR)
- SWX 1.18
- IDYA 1.57
- MACD
- SWX -0.08
- IDYA 0.11
- Stochastic Oscillator
- SWX 69.72
- IDYA 42.83
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.